keyword
MENU ▼
Read by QxMD icon Read
search

SCLC ICIs

keyword
https://read.qxmd.com/read/31015312/peripheral-blood-markers-identify-risk-of-immune-related-toxicity-in-advanced-non-small-cell-lung-cancer-treated-with-immune-checkpoint-inhibitors
#1
Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso, Ilaria Attili, Paola Del Bianco, Giulia Pasello, Valentina Guarneri, Giuseppe Aprile, PierFranco Conte, Laura Bonanno
BACKGROUND: Immune-checkpoint inhibitors (ICIs) are now standard of care for advanced non-small cell lung cancer (NSCLC). Unfortunately, many patients experience immune-related adverse events (irAEs), which are usually mild and reversible, but they require timely management and may be life threatening. No predictive markers of irAEs are available. MATERIALS AND METHODS: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were evaluated in patients with NSCLC consecutively treated with ICIs...
April 23, 2019: Oncologist
https://read.qxmd.com/read/31002952/advanced-stage-non-small-cell-lung-cancer-advances-in-thoracic-oncology-2018
#2
REVIEW
Jordi Remon, Myung-Ju Ahn, Nicolas Girard, Melissa Johnson, Dong-Wan Kim, Gilberto Lopes, Rathi N Pillai, Benjamin Solomon, Guillermo Villacampa, Qing Zhou
In 2018 research in the field of advanced non-small cell lung cancers (NSCLC) led to an expanded reach and impact of immune-checkpoint inhibitors (ICIs) as part of frontline treatment strategy, regardless of histology subtype, while ICI use was extended to include stage III disease, shifting the prognosis of all these patients. This new standard first-line approach opens a gap in standard second-line treatment, and older combinations may again become standard care after progression on ICIs. The characterization of predictive biomarkers, patient selection, the definition of strategies with ICI combinations upon progression on ICIs, as well as prospective evaluation of the efficacy of ICIs in subpopulations (such as patients with poor performance status or brain metastases) represent upcoming challenges in advanced thoracic malignancies...
April 16, 2019: Journal of Thoracic Oncology
https://read.qxmd.com/read/30999110/evaluation-of-the-lung-immune-prognostic-index-for-prediction-of-survival-and-response-in-patients-treated-with-atezolizumab-for-non-small-cell-lung-cancer-pooled-analysis-of-clinical-trials
#3
Michael J Sorich, Andrew Rowland, Christos S Karapetis, Ashley M Hopkins
INTRODUCTION: There is substantial variability in survival and response outcomes for patients using immune checkpoint inhibitors (ICIs), and predictive markers are required to guide treatment decisions. A lung immune prognostic index (LIPI) was recently developed to predict ICI treatment outcomes and we aim to evaluate whether LIPI is predictive of survival and response for patients treated with atezolizumab for advanced non-small cell lung cancer (NSCLC). METHODS: Pooled analysis of patient-level data of four clinical trials of atezolizumab for NSCLC...
April 15, 2019: Journal of Thoracic Oncology
https://read.qxmd.com/read/30987236/association-of-sarcopenia-with-and-efficacy-of-anti-pd-1-pd-l1-therapy-in-non-small-cell-lung-cancer
#4
Naoya Nishioka, Junji Uchino, Soichi Hirai, Yuki Katayama, Akihiro Yoshimura, Naoko Okura, Keiko Tanimura, Sachi Harita, Tatsuya Imabayashi, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama
Secondary sarcopenia is defined as a decrease in muscle mass due to disease or malnutrition. Several studies have reported that secondary sarcopenia is an indicator of postoperative recurrence. We hypothesized that there is a correlation between the effect of immune checkpoint inhibitors (ICIs) and sarcopenia. We retrospectively analyzed 38 patients with advanced non-small cell lung cancer (NSCLC) who were treated with ICIs between February 2016 and April 2018. Patients were divided into two groups according to the change rate of the psoas major muscle area (PMMA) at the L2-L3 position and investigated the correlation between the change rate of the PMMA and the efficacy of ICIs was investigated...
April 3, 2019: Journal of Clinical Medicine
https://read.qxmd.com/read/30964126/modulation-of-peripheral-blood-immune-cells-by-early-use-of-steroids-and-its-association-with-clinical-outcomes-in-patients-with-metastatic-non-small-cell-lung-cancer-treated-with-immune-checkpoint-inhibitors
#5
Giovanni Fucà, Giulia Galli, Marta Poggi, Giuseppe Lo Russo, Claudia Proto, Martina Imbimbo, Roberto Ferrara, Nicoletta Zilembo, Monica Ganzinelli, Antonio Sica, Valter Torri, Mario Paolo Colombo, Claudio Vernieri, Andrea Balsari, Filippo de Braud, Marina Chiara Garassino, Diego Signorelli
Background: Steroids are frequently used in patients with metastatic non-small cell lung cancer (mNSCLC), but they could be detrimental for patients treated with immune checkpoint inhibitors (ICIs). Here, we assessed the association between early use of steroids, clinical outcomes and peripheral immune blood cells modulation in patients with mNSCLC treated with ICIs. Methods: We reviewed patients with mNSCLC treated at our institution between April 2013 and December 2017...
2019: ESMO Open
https://read.qxmd.com/read/30950239/comparison-of-a-combination-of-chemotherapy-and-immune-checkpoint-inhibitors-and-immune-checkpoint-inhibitors-alone-for-the-treatment-of-advanced-and-metastatic-non-small-cell-lung-cancer
#6
Chih-Hsi Scott Kuo, Chin-Chou Wang, Yu-Chen Huang, Stelios Pavlidis, Chien-Ying Liu, How-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Chih-Liang Wang, Yi-Ke Guo, Cheng-Ta Yang
BACKGROUND: Single agent immune checkpoint inhibitors (ICIs) improve survival outcomes compared to chemotherapy for advanced non-small cell lung cancer (NSCLC), but treatment efficacy widely varies. The combination of ICIs with chemotherapy has shown promising efficacy over chemotherapy alone; however, whether this strategy is superior to single agent ICIs for the treatment of advanced NSCLC remains unknown. METHODS: The records of 109 patients with advanced NSCLC who were administered at least one cycle of ICIs were retrospectively reviewed...
April 5, 2019: Thoracic Cancer
https://read.qxmd.com/read/30937690/early-depth-of-tumor-shrinkage-and-treatment-outcomes-in-non-small-cell-lung-cancer-treated-using-nivolumab
#7
Hayato Kawachi, Daichi Fujimoto, Takeshi Morimoto, Kazutaka Hosoya, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii
Background It would be useful to have criteria for predicting long-term treatment responses to immune checkpoint inhibitors (ICIs). Maximum depth of response correlates with treatment outcomes among patients receiving programmed death protein 1 axis inhibitors for non-small cell lung cancer (NSCLC). We investigated associations between early depth of response and survival outcomes among patients receiving nivolumab for NSCLC. Methods Using records from prospective observational cohorts, we identified 83 previously treated advanced patients with NSCLC who received nivolumab during 2016-2017...
April 1, 2019: Investigational New Drugs
https://read.qxmd.com/read/30922388/use-of-targeted-next-generation-sequencing-to-characterize-tumor-mutational-burden-and-efficacy-of-immune-checkpoint-inhibition-in-small-cell-lung-cancer
#8
Biagio Ricciuti, Sasha Kravets, Suzanne E Dahlberg, Renato Umeton, Adem Albayrak, Safiya J Subegdjo, Bruce E Johnson, Mizuki Nishino, Lynette M Sholl, Mark M Awad
BACKGROUND: Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burden (TMB), as assessed by whole exome sequencing, correlates with improved clinical outcomes for patients with SCLC treated with ICIs. Whether TMB as assessed by targeted next generation sequencing (NGS) is associated with improved efficacy of ICIs in patients with SCLC is currently unknown...
March 28, 2019: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/30917841/a-nomogram-to-predict-survival-in-non-small-cell-lung-cancer-patients-treated-with-nivolumab
#9
Andrea Botticelli, Massimiliano Salati, Francesca Romana Di Pietro, Lidia Strigari, Bruna Cerbelli, Ilaria Grazia Zizzari, Raffaele Giusti, Marco Mazzotta, Federica Mazzuca, Michela Roberto, Patrizia Vici, Laura Pizzuti, Marianna Nuti, Paolo Marchetti
BACKGROUND: The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available to aid in treatment selection. METHODS: Patients with stage IIIB-IV NSCLC receiving nivolumab at Sant'Andrea Hospital and Regina Elena National Cancer Institute from June 2016 to July 2017 were enrolled onto this study...
March 27, 2019: Journal of Translational Medicine
https://read.qxmd.com/read/30913364/efficacy-of-subsequent-docetaxel-ramucirumab-and-s-1-after-nivolumab-for-patients-with-advanced-non-small-cell-lung-cancer
#10
Nobumasa Tamura, Hidehito Horinouchi, Katsutoshi Sekine, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
BACKGROUND: Cytotoxic chemotherapy for advanced non-small cell lung cancer (NSCLC) as second-line or subsequent treatment generally results in a poor treatment outcome. Several reports have indicated that subsequent cytotoxic chemotherapy in patients who have received immune checkpoint inhibitors (ICIs) might have relatively better efficacy. METHODS: The clinical data of advanced NSCLC patients treated with nivolumab during clinical practice at the National Cancer Center Hospital between 17 December 2015 and 31 August 2017 were consecutively reviewed, and the treatment outcomes of docetaxel-based chemotherapy (docetaxel +/- ramucirumab) or S-1 after nivolumab were analyzed...
March 26, 2019: Thoracic Cancer
https://read.qxmd.com/read/30887841/immune-checkpoint-based-therapy-in-myeloid-malignancies-a-promise-yet-to-be-fulfilled
#11
Jan Philipp Bewersdorf, Maximilian Stahl, Amer M Zeidan
Immune system evasion is essential for tumor cell survival and is mediated by the immunosuppressive tumor microenvironment and the activation of inhibitory immune checkpoints. While immune checkpoint-based therapy yielded impressive results in several advanced solid malignancies such as melanoma and non-small cell lung cancer, its role in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is still evolving. Areas covered: Here we review the immunology in the tumor microenvironment in the bone marrow and discuss the current preclinical and clinical data for immune checkpoint-based therapy in myeloid neoplasms...
March 19, 2019: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/30885338/the-association-between-tumor-burden-and-severe-immune-related-adverse-events-in-non-small-cell-lung-cancer-patients-responding-to-immune-checkpoint-inhibitor-treatment
#12
Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, Naoki Shingu, Yuko Yasuda, Yoshitomo Eguchi, Keisuke Anan, Junpei Hisanaga, Tatsuya Nitawaki, Miwa Iio, Yuko Sekido, Aiko Nakano, Takuro Sakagami
OBJECTIVES: The use of immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) has demonstrated survival benefits, although some treatment responders (defined as patients with non-progressive disease) are forced to discontinue treatment because of severe immune-related adverse events (irAEs). An association between treatment efficacy and irAEs has been reported. However, it is unclear which treatment responders are likely to develop severe irAEs. We aimed to examine risk factors for ICI-related severe irAEs in patients with NSCLC...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885333/nivolumab-refractory-patients-with-advanced-non-small-cell-lung-cancer
#13
A Costantini, V Fallet, J Corny, S Friard, C Chouaid, B Duchemann, E Giroux-Leprieur, L Taillade, L Doucet, S Brosseau, M Wislez, J Tredaniel, J Cadranel
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have revolutionised cancer care especially in lung cancer. New response patterns have been described under ICIs such as pseudo-progression or hyper-progressive disease (HPD). The definition of HPD is yet to be consensual. The aim of this study was to suggest a clinical definition of nivolumab-refractory patients and find factors associated with this entity. METHODS: We performed a multi centric retrospective study including all patients who received nivolumab for the treatment of advanced non-small cell lung cancer (NSCLC) during the French authorisation for temporary use in 2015...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30885328/antibiotics-are-associated-with-attenuated-efficacy-of-anti-pd-1-pd-l1-therapies-in-chinese-patients-with-advanced-non-small-cell-lung-cancer
#14
Sha Zhao, Guanghui Gao, Wei Li, Xuefei Li, Chao Zhao, Tao Jiang, Yijun Jia, Yayi He, Aiwu Li, Chunxia Su, Shengxiang Ren, Xiaoxia Chen, Caicun Zhou
OBJECTIVES: Gut microbiome plays a dominant role in modulating therapeutic efficacy of immune checkpoint inhibitors (ICIs) targeting the programmed cell death receptor/ligand-1 (PD-1/PD-L1) pathway, suggesting that co-administration of antibiotics (Abx), which might result in dysbacteriosis, can attenuate the clinical outcomes of ICIs. The current study aimed to investigate the predictive role of Abx on ICIs treatment in patients with advanced non-small cell lung cancer (NSCLC). The impact of proton pump inhibitors (PPIs), another medication that can induce dysbacteriosis, was also investigated...
April 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30867573/paraneoplastic-neurological-syndromes-in-the-era-of-immune-checkpoint-inhibitors
#15
REVIEW
Francesc Graus, Josep Dalmau
Paraneoplastic neurological syndromes (PNSs) comprise a group of disorders that can affect any part of the nervous system in patients with cancer and frequently result from autoimmune responses triggered by the ectopic expression of neuronal proteins in cancer cells. These disorders are rare, although the introduction of immune-checkpoint inhibitors (ICIs) into cancer treatment algorithms has renewed interest in PNSs. ICIs are associated with a considerably increased incidence of immunological toxicities compared with traditional anticancer therapies, including neurological immune-related adverse effects (nirAEs) that can manifest as PNSs...
March 12, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30863172/complete-response-associated-with-immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer-a-meta-analysis-of-nine-randomized-controlled-trials
#16
Jie Li, Qi He, Xiu Yu, Khalid Khan, Xuanwen Weng, Minjie Guan
Purpose: The purposes of this study were to investigate whether the use of immune checkpoint inhibitors (ICIs) in advanced non-small-cell lung cancer (NSCLC) would increase the possibility of archiving complete response (CR) and assess the surrogate end points for overall survival (OS). Methods: We calculated the incidence and relative risk (RR) of CR events in patients assigned to ICIs compared to that in controls. Simple linear regression models were fitted for median OS and each surrogate (median progression-free survival [PFS], CRs, and objective response rate [ORR])...
2019: Cancer Management and Research
https://read.qxmd.com/read/30848091/pretreatment-lactate-dehydrogenase-may-predict-outcome-of-advanced-non-small-cell-lung-cancer-patients-treated-with-immune-checkpoint-inhibitors-a-meta-analysis
#17
Zhibo Zhang, Ye Li, Xiang Yan, Qi Song, Guoqiang Wang, Yi Hu, Shunchang Jiao, Jinliang Wang
The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for peripheral blood biomarker of LDH in advanced NSCLC patients treated with ICIs. We extracted the hazard ratio (HR) with 95% confidence interval (CI) for the progression free survival (PFS) and overall survival (OS) and performed meta-analysis of HR...
March 7, 2019: Cancer Medicine
https://read.qxmd.com/read/30825132/first-line-treatment-of-non-small-cell-lung-cancer-nsclc-with-immune-checkpoint-inhibitors
#18
REVIEW
Olivier Bylicki, Helene Barazzutti, Nicolas Paleiron, Jacques Margery, Jean-Baptiste Assié, Christos Chouaïd
Treatment of advanced-stage or metastatic non-small-cell lung cancers (NSCLCs) without EGFR mutations or ALK rearrangements, which can now be treated with molecularly targeted therapies, had been based on cytotoxic chemotherapy for a long time. Immune checkpoint inhibitors (ICIs), notably antibodies directed against programmed cell-death protein-1 (PD-1) and its ligand (PD-L1) have transformed therapeutic standards in thoracic oncology. These ICIs are now the reference second-line treatment and numerous phase III trials have examined their efficacy in treatment-naïve patients...
March 2, 2019: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://read.qxmd.com/read/30824587/immunotherapy-in-non-small-cell-lung-cancer-facts-and-hopes
#19
Deborah B Doroshow, Miguel F Sanmamed, Katherine Hastings, Katerina Politi, David L Rimm, Lieping Chen, Ignacio Melero, Kurt A Schalper, Roy S Herbst
Immune checkpoint inhibitors (ICIs), particularly inhibitors of the PD-1 axis, have altered the management of non-small cell lung cancer (NSCLC) over the last ten years. First demonstrated to improve outcomes in second-line or later therapy of advanced disease, ICIs were shown to improve overall survival (OS) compared to chemotherapy in first line therapy for patients whose tumors express PD-L1 on at least 50% of cells. More recently, combining ICIs with chemotherapy has been shown to improve survival in patients with both squamous and nonsquamous NSCLC, regardless of PD-L1 expression...
March 1, 2019: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://read.qxmd.com/read/30819829/pd-1-pd-l1-blockade-therapy-in-advanced-non-small-cell-lung-cancer-current-status-and-future-directions
#20
Liliang Xia, Yuanyong Liu, Ying Wang
The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune responses mediated by the tumors. Among multiple immune modulators identified, the programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis leading to the exhaustion of T-cell immunity in chronic infections and tumors has been widely investigated...
February 2019: Oncologist
keyword
keyword
161397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"